AIA expands cancer benefit reach

The benefit, which funds Medsafe-approved medicines not funded by Pharmac, had previously only been available as an add-on to AIA’s Real Trauma policies.

This has now been expanded to include Real life and total permanent disability policies.

“AIA New Zealand was the first to see a gap in the market for the Cancer Treatment Benefit, which we launched in March this year. Sales to date have been very encouraging,”  David Savidan, AIA New Zealand’s head of marketing and product, said.

“Detecting cancer early, and getting access to the new generation of proven immunotherapy medicines, can greatly improve a person’s chances of surviving cancer.”